HC Wainwright & Co. Reiterates Buy on Jasper Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on Jasper Therapeutics (NASDAQ:JSPR) and maintained a $65 price target.
August 13, 2024 | 6:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on Jasper Therapeutics and maintained a $65 price target.
The reiteration of a Buy rating and the maintenance of a $65 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100